Patents by Inventor Thierry Wurch
Thierry Wurch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230406940Abstract: The invention relates to a novel antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor, with an improved antagonistic activity, said antibody comprising a modified hinge region. The invention also relates to a composition comprising such an antibody antagonist to c-Met and its use as a medicament for treating cancer.Type: ApplicationFiled: December 21, 2022Publication date: December 21, 2023Inventors: Liliane GOETSCH, Thierry WURCH, Cédric BES
-
Publication number: 20210087278Abstract: The invention relates to a novel antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor, with an improved antagonistic activity, said antibody comprising a modified hinge region. The invention also relates to a composition comprising such an antibody antagonist to c-Met and its use as a medicament for treating cancer.Type: ApplicationFiled: March 16, 2020Publication date: March 25, 2021Applicant: PIERRE FABRE MEDICAMENTInventors: Liliane GOETSCH, Thierry WURCH, Cédric BES
-
Publication number: 20190359717Abstract: The invention relates to a novel antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor, with an improved antagonistic activity, said antibody comprising a modified hinge region. The invention also relates to a composition comprising such an antibody antagonist to c-Met and its use as a medicament for treating cancer.Type: ApplicationFiled: January 4, 2019Publication date: November 28, 2019Applicant: PIERRE FABRE MEDICAMENTInventors: Liliane GOETSCH, Thierry WURCH, Cédric BES
-
Publication number: 20180142024Abstract: The invention relates to a novel antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor, with an improved antagonistic activity, said antibody comprising a modified hinge region. The invention also relates to a composition comprising such an antibody antagonist to c-Met and its use as a medicament for treating cancer.Type: ApplicationFiled: December 15, 2017Publication date: May 24, 2018Applicant: Pierre Fabre MedicamentInventors: Liliane Goetsch, Thierry Wurch, Cédric Bes
-
Publication number: 20170218071Abstract: The invention relates to a novel antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor, with an improved antagonistic activity, said antibody comprising a modified hinge region. The invention also relates to a composition comprising such an antibody antagonist to c-Met and its use as a medicament for treating cancer.Type: ApplicationFiled: September 7, 2016Publication date: August 3, 2017Applicant: Pierre Fabre MedicamentInventors: Liliane Goetsch, Thierry Wurch, Cédric Bes
-
Patent number: 9676839Abstract: The present disclosure relates to the antibody engineering field and, more particularly, to a process for the screening of antibodies and/or the modulation of the agonistic/antagonistic activity of antibodies. More particularly, the disclosure concerns a process of improving the antagonistic activity of a monoclonal antibody directed against a specific target molecule, or a divalent functional fragment or derivative thereof, the antibody being capable of inhibiting one or more of the biological activities of the target molecule, wherein the process comprises a stage of reconfiguration of the hinge region consisting of a modification of the amino acid sequence of the hinge region by the deletion, the addition or the substitution of at least one amino acid. The disclosure also relates to polypeptides useful for such a modulation method and the obtained antibodies.Type: GrantFiled: December 2, 2009Date of Patent: June 13, 2017Assignee: PIERRE FABRE MEDICAMENTInventors: Liliane Goetsch, Thierry Wurch
-
Patent number: 9469691Abstract: Antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor, with an improved antagonistic activity, said antibody comprising a modified hinge region. A composition comprising such an antibody antagonist to c-Met and its use as a medicament for treating cancer.Type: GrantFiled: April 9, 2014Date of Patent: October 18, 2016Assignee: PIERRE FABRE MEDICAMENTInventors: Liliane Goetsch, Thierry Wurch, Cédric Bes
-
Publication number: 20160159911Abstract: Antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor, with an improved antagonistic activity, said antibody comprising a modified hinge region. A composition comprising such an antibody antagonist to c-Met and its use as a medicament for treating cancer.Type: ApplicationFiled: April 9, 2014Publication date: June 9, 2016Applicant: Pierre Fabre MedicamentInventors: Liliane GOETSCH, Thierry Wurch, Cédric Bes
-
Publication number: 20160039935Abstract: The present invention relates to a novel divalent antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor, preferably both in a ligand-dependent and in a ligand-independent manner as well as the amino acid and nucleic acid sequences coding for said antibody. More preferably said antibody comprises a modified hinge region and exhibits an improved antagonistic activity. More particularly, the antibody according to the invention is capable of inhibiting the c-Met dimerization. The invention likewise comprises the use of said antibody as a medicament for the prophylactic and/or therapeutic treatment of cancers, preferably for cancer characterized by a ligand-independent activation of c-Met, or any pathology connected with the over expression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the over-expression of c-Met.Type: ApplicationFiled: April 2, 2015Publication date: February 11, 2016Applicant: Pierre Fabre MedicamentInventors: Liliane GOETSCH, Thierry Wurch, Cédric Bes
-
Publication number: 20150307613Abstract: The invention relates to a novel antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor both is a ligand-dependent and in a ligand-independent manner, with an improved antagonistic activity, said antibody comprising a modified hinge region. The invention also relates to a composition comprising such an antibody antagonist to c-Met and its use as a medicament for treating cancer.Type: ApplicationFiled: February 27, 2015Publication date: October 29, 2015Inventors: Liliane GOETSCH, Thierry Wurch, Cedric Bes
-
Publication number: 20150291696Abstract: Antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor, with an improved antagonistic activity, said antibody comprising a modified hinge region. A composition comprising such an antibody antagonist to c-Met and its use as a medicament for treating cancer.Type: ApplicationFiled: April 9, 2014Publication date: October 15, 2015Applicant: Pierre Fabre MedicamentInventors: Liliane GOETSCH, Thierry Wurch, Cédric Bes
-
Publication number: 20150239958Abstract: The present disclosure relates to the antibody engineering field and, more particularly, to a process for the screening of antibodies and/or the modulation of the agonistic/antagonistic activity of antibodies. More particularly, the disclosure concerns a process of improving the antagonistic activity of a monoclonal antibody directed against a specific target molecule, or a divalent functional fragment or derivative thereof, the antibody being capable of inhibiting one or more of the biological activities of the target molecule, wherein the process comprises a stage of reconfiguration of the hinge region consisting of a modification of the amino acid sequence of the hinge region by the deletion, the addition or the substitution of at least one amino acid. The disclosure also relates to polypeptides useful for such a modulation method and the obtained antibodies.Type: ApplicationFiled: February 25, 2015Publication date: August 27, 2015Applicant: PIERRE FABRE MEDICAMENTInventor: Thierry Wurch
-
Patent number: 8765128Abstract: Antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor, with an improved antagonistic activity, said antibody comprising a modified hinge region. A composition comprising such an antibody antagonist to c-Met and its use as a medicament for treating cancer.Type: GrantFiled: September 14, 2012Date of Patent: July 1, 2014Assignee: Pierre Fabre MedicamentInventors: Liliane Goetsch, Thierry Wurch, Cédric Bes
-
Patent number: 8747850Abstract: Antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor, with an improved antagonistic activity, said antibody comprising a modified hinge region. A composition comprising such an antibody antagonist to c-Met and its use as a medicament for treating cancer.Type: GrantFiled: September 14, 2012Date of Patent: June 10, 2014Assignee: Pierre Fabre MedicamentInventors: Liliane Goetsch, Thierry Wurch, Cédric Bes
-
Patent number: 8741290Abstract: Antibodies capable of binding to the human c-Met receptor and/or capable of inhibiting the tyrosine kinase activity of said receptor, with an improved antagonistic activity, the antibodies comprising a modified hinge region. A composition comprising one or more of such antibodies antagonist to c-Met and its use as a medicament for treating cancer.Type: GrantFiled: December 2, 2009Date of Patent: June 3, 2014Assignee: Pierre Fabre MedicamentInventors: Liliane Goetsch, Thierry Wurch, Cédric Bes
-
Patent number: 8729249Abstract: Antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor, with an improved antagonistic activity, said antibody comprising a modified hinge region. A composition comprising such an antibody antagonist to c-Met and its use as a medicament for treating cancer.Type: GrantFiled: September 14, 2012Date of Patent: May 20, 2014Assignee: Pierre Fabre MedicamentInventors: Liliane Goetsch, Thierry Wurch, Cédric Bes
-
Publication number: 20140115727Abstract: The invention relates to a novel antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor both in a ligand-dependent and in a ligand-independent manner, with an improved antagonistic activity, said antibody comprising a modified hinge region. The invention also relates to a composition comprising such an antibody antagonist to c-Met and its use as a medicament for treating cancer.Type: ApplicationFiled: August 29, 2013Publication date: April 24, 2014Applicant: Pierre Fabre MedicamentInventors: Liliane Goetsch, Thierry Wurch, Cedric Bes
-
Publication number: 20140112911Abstract: The present invention relates to a novel divalent antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor, preferably both in a ligand-dependent and in a ligand-independent manner as well as the amino acid and nucleic acid sequences coding for said antibody. More preferably said antibody comprises a modified hinge region and exhibits an improved antagonistic activity. More particularly, the antibody according to the invention is capable of inhibiting the c-Met dimerization. The invention likewise comprises the use of said antibody as a medicament for the prophylactic and/or therapeutic treatment of cancers, preferably for cancer characterized by a ligand-independent activation of c-Met, or any pathology connected with the over expression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the over-expression of c-Met.Type: ApplicationFiled: June 1, 2011Publication date: April 24, 2014Inventors: Liliane Goetsch, Thierry Wurch, Cédric Bes
-
Patent number: 8545839Abstract: The invention relates to a novel antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor both in a ligand-dependent and in a ligand-independent manner, with an improved antagonistic activity, said antibody comprising a modified hinge region. The invention also relates to a composition comprising such an antibody antagonist to c-Met and its use as a medicament for treating cancer.Type: GrantFiled: June 1, 2010Date of Patent: October 1, 2013Assignee: Pierre Fabre MedicamentInventors: Liliane Goetsch, Thierry Wurch, Cédric Bes
-
Publication number: 20130216527Abstract: The present invention relates to a novel divalent antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor, preferably both in a ligand-dependent and in a ligand-independent manner as well as the amino acid and nucleic acid sequences coding for said antibody. More preferably said antibody comprises a modified hinge region and exhibits an improved antagonistic activity. More particularly, the antibody according to the invention is capable of inhibiting the c-Met dimerization. The invention likewise comprises the use of said antibody as a medicament for the prophylactic and/or therapeutic treatment of cancers, preferably for cancer characterized by a ligand-independent activation of c-Met, or any pathology connected with the over expression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the over-expression of c-Met.Type: ApplicationFiled: June 1, 2011Publication date: August 22, 2013Inventors: Liliane Goetsch, Thierry Wurch, Bes Cédric